Clinical trials: Liraglutide, open to volunteers
Amyotrophic Lateral Sclerosis
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design. This experiment is divided into two groups: the experimental drug group and the placebo group.
- Trial name
- NCT06726577
- Testing
- TP04HN106, Saline
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- ADIPO-CKD (NCT07309094)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor, Tirzepatide
- Where
- Spain
- Volunteers
- 250 people
- Sponsor
- Cardenal Herrera University
Obesity, Adolescent
Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone
The aim of the study is to investigate the effects of preoperative Saxenda (liraglutide). There are two groups, one group receives Saxena in addition to dietary measures when first seeking the operation, one group only diet.
- Trial name
- NCT06865365
- Testing
- Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions, Dietologic measures and lifestyle optimization for weight loss
- Volunteers
- 72 people
- Sponsor
- Medical University of Vienna
Abdominal Wall Hernia
Preoperative Weight Loss for Open Abdominal Wall Reconstruction
The goal of this randomized controlled trial is to compare preoperative intensive weight management to upfront surgery in obese patients undergoing complex abdominal wall reconstruction.
- Trial name
- NCT05925959
- Testing
- Preoperative Weight Management Program
- Where
- 2 sites in United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Benjamin T. Miller
Obesity
Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected)…
- Trial name
- NCT07225816
- Testing
- Liraglutide, Oral Semaglutide, Semaglutide
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
PCOS, Obesity
Liraglutide Treatment in Obese Infertile PCOS Women
Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug…
- Conditions
- PCOS, Obesity, Infertility
- Trial name
- LITOP (NCT06742710)
- Testing
- Liraglutide and metformin, Metformin
- Where
- 3 sites in China
- Volunteers
- 890 people
- Sponsor
- Peking University Third Hospital
Type 2 Diabetes Patients, Overweight and Obesity
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin…
- Conditions
- Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
- Trial name
- LiraGooD (NCT03087032)
- Testing
- Liraglutide, insulin glargine
- Where
- China
- Volunteers
- 164 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Obesity
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
The goal of this observational study is to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults who get their health insurance through their employers.
- Trial name
- NCT07640139
- Testing
- Incretin-based therapies (GLP-1 and GLP-1/GIP)
- Where
- United States
- Volunteers
- 125,000 people
- Sponsor
- Indiana University
Diabete Type 2
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05268237
- Testing
- Liraglutide
- Where
- Hong Kong
- Volunteers
- 15 people
- Sponsor
- Biolingus
Metabolic Syndrome
Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume…
- Trial name
- ZQL008 (NCT04575844)
- Testing
- Liraglutide, Exercise training, Liraglutide + Exercise training
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Diabetes, Diabetes Mellitus, Type 2
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
- Trial name
- NCT01511393
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 6,750 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight, Diabetes (DM)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength)…
- Trial name
- NCT07702461
- Testing
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Ohio State University
Type 2 Diabetic Patients
A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus
A randomized open, positive parallel controlled clinical study design was adopted. Participants were randomly assigned 1:1 according to inclusion criteria and exclusion criteria into two treatment regiments: Delu insulin…
- Trial name
- TLI vs PMI (NCT06925334)
- Testing
- Degludec insulin
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Overweight and Obese Adults
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.
To evaluate the differences in weight loss between liraglutide monotherapy and combined with orlistat in overweight/obese patients.
- Trial name
- NCT07301437
- Testing
- liraglutide monotherapy, liraglutide combined with orlistat
- Volunteers
- 120 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Childhood Obesity, Treatment Adherence
The Evira Study: Additional Support During Obesity Treatment
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity.
- Trial name
- NCT06836284
- Testing
- Digi-physical treatment tool, Evira, Obesity medication with liraglutide or semaglutide
- Where
- 3 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Delirium, Postoperative
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
- Trial name
- NCT06361238
- Testing
- Liraglutide injection
- Where
- China
- Volunteers
- 260 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Obesity & Overweight
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that…
- Trial name
- GLP-BARI-VAN (NCT07901777)
- Testing
- GLP-1 Receptor Agonist Therapy, Laparoscopic Sleeve Gastrectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Yuzuncu Yil University
Maturity Onset Diabetes of the Young
Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)
The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY).
- Trial name
- NCT07029009
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mansa
Obesity (BMI Equal to or >30), Weight Regain After Bariatric Surgery
Changes in Body Composition Following Pharmacological Treatment for Obesity.
Background: Intentional weight loss via various treatments results in a loss of lean mass of approximately 10% for every 10 kg of total weight lost.
- Trial name
- NCT07908940
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Hospital San Carlos, Madrid